Perrigo Company plc (NYSE:PRGO – Get Free Report) saw some unusual options trading activity on Friday. Stock traders acquired 11,734 call options on the company. This is an increase of 637% compared to the typical daily volume of 1,593 call options.
Perrigo Stock Performance
Shares of PRGO opened at $28.98 on Friday. Perrigo has a 1 year low of $23.14 and a 1 year high of $33.46. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.56 and a quick ratio of 1.77. The stock’s fifty day moving average price is $24.94 and its two-hundred day moving average price is $26.20. The firm has a market cap of $3.95 billion, a PE ratio of -24.76 and a beta of 0.54.
Perrigo (NYSE:PRGO – Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported $0.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.92 by $0.01. The business had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.20 billion. Perrigo had a positive return on equity of 7.38% and a negative net margin of 3.64%. On average, equities research analysts forecast that Perrigo will post 2.56 EPS for the current year.
Perrigo Increases Dividend
Insider Activity at Perrigo
In other news, Director Jeffrey B. Kindler sold 17,598 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $28.27, for a total value of $497,495.46. Following the completion of the transaction, the director now directly owns 5,409 shares of the company’s stock, valued at $152,912.43. This represents a 76.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.40% of the stock is owned by insiders.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of PRGO. Headlands Technologies LLC lifted its position in shares of Perrigo by 1,942.0% during the fourth quarter. Headlands Technologies LLC now owns 1,409 shares of the company’s stock worth $36,000 after acquiring an additional 1,340 shares in the last quarter. Versant Capital Management Inc purchased a new stake in Perrigo during the 4th quarter worth about $45,000. GAMMA Investing LLC boosted its stake in Perrigo by 93.7% in the 4th quarter. GAMMA Investing LLC now owns 1,920 shares of the company’s stock worth $49,000 after purchasing an additional 929 shares during the period. Central Pacific Bank Trust Division boosted its stake in Perrigo by 33.3% in the 4th quarter. Central Pacific Bank Trust Division now owns 2,000 shares of the company’s stock worth $51,000 after purchasing an additional 500 shares during the period. Finally, Venturi Wealth Management LLC bought a new stake in shares of Perrigo during the third quarter valued at about $56,000. 95.91% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
PRGO has been the subject of a number of recent analyst reports. Piper Sandler downgraded Perrigo from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $34.00 to $27.00 in a research note on Monday, January 6th. Argus lowered shares of Perrigo from a “buy” rating to a “hold” rating in a research report on Tuesday, January 14th. Finally, StockNews.com lowered shares of Perrigo from a “buy” rating to a “hold” rating in a research report on Wednesday, February 19th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $33.00.
Read Our Latest Stock Analysis on PRGO
Perrigo Company Profile
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.
Featured Stories
- Five stocks we like better than Perrigo
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Analysts Lift Archer Aviation Stock Despite Earnings Miss
- How to Read Stock Charts for Beginners
- 5 Best Gold ETFs for March to Curb Recession Fears
- What is a Bond Market Holiday? How to Invest and Trade
- 3 Stocks for Your Watchlist: Unlocking Tomorrow’s Winners Today
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.